27984052|t|Beta-Adrenergic Receptor Blockers in Hypertension: Alive and Well
27984052|a|Beta-adrenergic receptor blockers (β-blockers) are an appropriate treatment for patients having systemic hypertension (HTN) who have concomitant ischemic heart disease (IHD), heart failure, obstructive cardiomyopathy, aortic dissection or certain cardiac arrhythmias. β-Blockers can be used in combination with other antiHTN drugs to achieve maximal blood pressure control. Labetalol can be used in HTN emergencies and urgencies. β-Blockers may be useful in HTN patients having a hyperkinetic circulation (palpitations, tachycardia, HTN, and anxiety), migraine headache, and essential tremor. β-Blockers are highly heterogeneous with respect to various pharmacologic properties: degree of intrinsic sympathomimetic activity, membrane stabilizing activity, β1 selectivity, α1-adrenergic blocking effects, tissue solubility, routes of systemic elimination, potencies and duration of action, and specific properties may be important in the selection of a drug for clinical use. β-Blocker usage to reduce perioperative myocardial ischemia and cardiovascular (CV) complications may not benefit as many patients as was once hoped, and may actually cause harm in some individuals. Currently the best evidence supports perioperative β-blocker use in two patient groups: patients undergoing vascular surgery with known IHD or multiple risk factors for it, and for those patients already receiving β-blockers for known CV conditions.
27984052	0	33	Beta-Adrenergic Receptor Blockers	T103	UMLS:C0001645
27984052	37	49	Hypertension	T038	UMLS:C0020538
27984052	66	99	Beta-adrenergic receptor blockers	T103	UMLS:C0001645
27984052	101	111	β-blockers	T103	UMLS:C0001645
27984052	132	141	treatment	T058	UMLS:C0087111
27984052	162	183	systemic hypertension	T038	UMLS:C0020538
27984052	185	188	HTN	T038	UMLS:C0020538
27984052	199	233	concomitant ischemic heart disease	T038	UMLS:C0151744
27984052	235	238	IHD	T038	UMLS:C0151744
27984052	241	254	heart failure	T038	UMLS:C0018801
27984052	256	282	obstructive cardiomyopathy	T038	UMLS:C0007194
27984052	284	301	aortic dissection	T038	UMLS:C0340643
27984052	313	332	cardiac arrhythmias	T033	UMLS:C0003811
27984052	334	344	β-Blockers	T103	UMLS:C0001645
27984052	383	396	antiHTN drugs	T103	UMLS:C0003364
27984052	408	438	maximal blood pressure control	T038	UMLS:C1753303
27984052	440	449	Labetalol	T103	UMLS:C0022860
27984052	465	480	HTN emergencies	T038	UMLS:C0745136
27984052	485	494	urgencies	T038	UMLS:C0745138
27984052	496	506	β-Blockers	T103	UMLS:C0001645
27984052	524	527	HTN	T038	UMLS:C0020538
27984052	559	570	circulation	T038	UMLS:C0005775
27984052	572	584	palpitations	T033	UMLS:C0030252
27984052	586	597	tachycardia	T038	UMLS:C0039231
27984052	599	602	HTN	T038	UMLS:C0020538
27984052	608	615	anxiety	T033	UMLS:C0003467
27984052	618	635	migraine headache	T038	UMLS:C0149931
27984052	641	657	essential tremor	T038	UMLS:C0270736
27984052	659	669	β-Blockers	T103	UMLS:C0001645
27984052	745	789	degree of intrinsic sympathomimetic activity	T033	UMLS:C0877014
27984052	822	836	β1 selectivity	T038	UMLS:C1152727
27984052	838	868	α1-adrenergic blocking effects	T038	UMLS:C1152724
27984052	889	919	routes of systemic elimination	T033	UMLS:C0231360
27984052	1003	1039	selection of a drug for clinical use	T062	UMLS:C0013175
27984052	1081	1100	myocardial ischemia	T038	UMLS:C0151744
27984052	1105	1138	cardiovascular (CV) complications	T038	UMLS:C0161816
27984052	1348	1364	vascular surgery	T058	UMLS:C0042381
27984052	1376	1379	IHD	T038	UMLS:C0151744
27984052	1454	1464	β-blockers	T103	UMLS:C0001645
27984052	1475	1488	CV conditions	T038	UMLS:C0161816